Group 1 - The company has triggered the conditional redemption clause for its convertible bonds, "诺泰转债," as the stock price met the required conditions [1][2] - The board of directors approved the early redemption of "诺泰转债" during a meeting on April 2, 2025, and the details were disclosed on the Shanghai Stock Exchange [2][3] - The redemption date is set for April 24, 2025, with a redemption price of 100.1436 CNY per bond, which includes accrued interest [3][5] Group 2 - A total of 4,044,000 CNY (40,440 bonds) will be redeemed, with a total payout amount of 4,049,809.65 CNY, including interest [4][6] - The redemption payment date is April 25, 2025, and the bonds will be delisted on the same day [4][6] - As of the redemption date, the remaining balance of "诺泰转债" will be 4,044,000 CNY, representing 0.9318% of the total issuance, while 429,956,000 CNY has already been converted into shares [7] Group 3 - The early redemption will not have a significant impact on the company's financial condition, operating results, or cash flow, and will not affect the normal use of the raised funds [7] - Following the redemption, the company's total share capital will increase to 224,870,915 shares, which may dilute earnings per share in the short term [7]
江苏诺泰澳赛诺生物制药股份有限公司 关于“诺泰转债”赎回结果暨股份变动的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-04-27 08:23